68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis.
Adult
Aged
Cardiomyopathies
/ diagnostic imaging
False Positive Reactions
Female
Fluorodeoxyglucose F18
Humans
Male
Middle Aged
Octreotide
/ analogs & derivatives
Organometallic Compounds
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Sarcoidosis
/ diagnostic imaging
Sensitivity and Specificity
Treatment Outcome
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
1
7
2020
medline:
30
10
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to F-FDG uptake, which reflects nonspecific leukocyte infiltration, Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive F-FDG PET/CT results.
Identifiants
pubmed: 32604122
doi: 10.1097/RLU.0000000000003185
pii: 00003072-202009000-00035
doi:
Substances chimiques
Ga(III)-DOTATOC
0
Organometallic Compounds
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e416-e418Références
Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017;24:1741–1758.
Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–1323.
Dweck M, Abgral R, Trivieri MG, et al. Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging. 2018;11:94–107.
Young L, Sperry BW, Hachamovitch R. Update on treatment in cardiac sarcoidosis. Curr Treat Options Cardiovasc Med. 2017;19:47.
Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009;20:578–583.
Abgral R, Dweck MR, Trivieri MG, et al. Clinical utility of combined FDG-PET/MR to assess myocardial disease. JACC Cardiovasc Imaging. 2017;10:594–597.
Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging. 2018;11:e007030.
Ishida Y, Yoshinaga K, Miyagawa M, et al. Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med. 2014;28:393–403.
Gormsen LC, Haraldsen A, Kramer S, et al. A dual tracer 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res. 2016;6:52.